EUFETS is a pioneer in the production of retroviral vectors for clinical use and has been involved in a multitude of clinical trials in gene therapy. As of 2005 vectors have been produced for 6 different trials in Germany, Switzerland, the UK and France. These include trials for inherited immune deficiencies, cancer, and HIV infection.

In addition to this, gene-modified cells (haematopoietic stem cells, T-cells) have been produced for 3 different trials in Germany as well as in Switzerland. So far EUFETS has produced more than 1000 cell therapy products used to treat patients throughout Europe and the US.

»More than 1000 products for cellular therapies: peripheral stem cells, bone marrow, cord blood,
CD34+ stem cells, donor lymphocytes
»GvHD suicide gene therapy: vector production & T-cell transduction
»ADA SCID gene therapy: vector production
»CGD gene therapy: vector production & stem cell transduction
»Anti-HIV gene therapy: vector production & CD4+ T-cell transduction
»Cancer gene therapy (chimeric T cell receptors): vector production